The Democratic Republic of the Congo began the Tumaini ('hope' in Swahili) vaccine trial against the Bundibugyo strain of Ebola on 23 October 2026, with first doses given in Bunia, Ituri Province.
The first product tested is Ervebo, which is licensed only against Zaire ebolavirus; no vaccine is licensed for Bundibugyo virus disease.
Two Bundibugyo-specific candidates are due to join: ChAdOx1 Bundibugyo (University of Oxford and Serum Institute of India) and Moderna's mRNA-1469, both backed by CEPI.
The Phase 2/3 adaptive trial uses ring vaccination. The DRC had recorded 9,552 cases and 4,602 deaths by 21 October in an outbreak WHO declared a PHEIC on 17 May 2026.
| Vaccine | Developer | Platform | Status |
|---|---|---|---|
| Ervebo | Merck | Live recombinant vesicular stomatitis virus vector | Licensed for Zaire ebolavirus; first product dosed, 23 Oct 2026 |
| ChAdOx1 Bundibugyo | University of Oxford and Serum Institute of India | Adenoviral vector | Bundibugyo-specific; due to join, CEPI-backed |
| mRNA-1469 | Moderna | mRNA | Bundibugyo-specific; due to join, CEPI-backed |
Instead of vaccinating a whole population, health workers vaccinate the contacts of each confirmed case and, where needed, the contacts of those contacts. It builds a ring of immunity around every case and, in a trial, tests the vaccine on those most exposed.
Simple Analogy: Like a firebreak cut around each spark rather than soaking the whole forest.
Declared the outbreak a PHEIC; supports the trial
Funds the Tumaini trial and the two Bundibugyo-specific candidates
DR Congo's national biomedical research institute; trial co-sponsor
Bundibugyo species first identified, in the outbreak in Uganda's Bundibugyo district (2007-08)
Bundibugyo outbreak in Isiro, DR Congo
DR Congo confirms an Ebola outbreak in Ituri Province
WHO declares it a Public Health Emergency of International Concern
Nigeria confirms its first case of the outbreak
Tumaini trial begins in Bunia with Ervebo
GS Paper III > Science and Technology > Health, vaccines
General Awareness > Science, diseases
An Orthoebolavirus species first identified in Uganda in 2007; no licensed vaccine exists for it
A vaccine's ability to trigger an immune response
Public Health Emergency of International Concern, WHO's highest alert under the International Health Regulations (2005)